These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000345-38 EFFICACY AND SAFETY OF BAL4079 IN THE TREATMENT OF SEVERE REFRACTORY CHRONIC HAND DERMATITIS. 2007-09-13 due-trials
Reported results 2004-000432-85 Follow up Efficacy and safety Study of BAL4079 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Therapy 2007-05-21 due-trials
Reported results 2004-001662-41 A Phase III, Randomized, Double-Blind Study of Ceftobiprole versus Vancomycin in the Treatment of Complicated Skin and Skin Structure Infections 2006-02-22 due-trials
Reported results 2004-001730-17 A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF CEFTOBIPROLE VERSUS LINEZOLID PLUS CEFTAZIDIME IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA 2007-05-29 due-trials
Reported results 2005-004776-20 Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis 2007-05-09 due-trials
Reported results 2005-005294-30 Open-label, multi-center, sequential group, clinical study to determine the safety and efficacy of escalating dosing regimens of intravenous or oral BAL8557 in the prophylaxis of patients undergoing c... 2007-05-18 due-trials
Reported results 2006-003868-59 A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filame... 2013-03-28 due-trials
Reported results 2006-003951-18 A PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BAL8557 VERSUS A CASPOFUNGIN FOLLOWED BY VORICONAZOLE REGIMEN IN THE TREATMENT OF CANDIDEMIA AND OTHER INVASIVE CANDI... 2015-03-03 due-trials
Reported results 2006-003959-21 Open label treatment of patients with chronic hand dermatitis who have participated in a clincal trial involving oral alitretinoin 2009-03-30 due-trials
Reported results 2006-005003-33 Estudio abierto de Isavuconazol en el tratamietno de pacientes con aspergilosis y deterioro de la función renal o de pacientes con enfermedad fúngica invasiva causada por mohos atípicos, levaduras u h... 2016-05-05 due-trials
Exempt, with results 2010-024237-23 An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors 2016-04-06 not-yet-due
Trial is partly outside EEC, and reported results 2013-004614-18 An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment with Systemic Antibiotics 2020-07-07 bad-data
Trial is partly outside EEC, and reported results 2013-004615-45 A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephalosp... 2020-03-16 bad-data
Exempt, with results 2014-003371-34 An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma 2022-11-24 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2016-004448-12 A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Studio pilota di ARQ in soggetti con colangiocarcinoma intraepatico ino... 2022-10-25 bad-data
Reported results 2017-001605-32 A randomized, double-blind, multicenter study to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin s... 2019-04-22 due-trials
Reported results 2017-001699-43 A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including inf... 2022-03-11 due-trials
Exempt, with results 2019-000359-15 An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02) Un estudio Fase 1b/2, abi... 2022-08-04 not-yet-due
Exempt, with results 2019-004505-27 A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aber... 2022-12-29 not-yet-due
Trial is partly outside EEC 2022-001837-35 A multicenter, open-label, single-arm, multiple-dose study to evaluate the safety, pharmacokinetics, and efficacy of ceftobiprole medocaril in term and pre-term neonates and infants up to 3 months of ... bad-data